Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody
about
Current and emerging treatment options in the management of lupusKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsProduction and application of polyclonal and monoclonal antibodies against Spiroplasma eriocheiris.Immunotherapies in Late-Stage Development for Patients With Severe SLE and/or Lupus Nephritis.Advances in phage display technology for drug discovery.Self-reactive IgE exacerbates interferon responses associated with autoimmunity.Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus ErythematosusOverview of pathophysiology and treatment of human lupus nephritis.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Application of phage peptide display technology for the study of food allergen epitopes.Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab.An era of biological treatment in systemic lupus erythematosus.Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.Antibodies to watch in 2018.Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers.
P2860
Q26741266-CBD3F7BF-B3D6-438B-B2F7-A3A8F98BCF0AQ26775756-AD16D45E-898B-493C-AFC2-66965AE09B65Q31030401-9C686EB2-A548-407A-84FC-370FB37E4A9EQ33714219-6A64A179-8DD1-48A6-9B95-14EE2AB90347Q35614190-02D5604F-28D5-4709-B4B6-13C548456B99Q36479577-6C292ADD-E01F-487C-A233-473A14B36D9DQ37287000-EA9B344D-8251-44E8-8775-5AB35DBBC0E0Q37633408-3267B56B-10F0-4B3A-B1C2-BD803084E28EQ38876110-7A18139E-3F4B-419F-9EC8-DA87AAAF2CC4Q38888137-0B5A041C-2A93-414C-9F40-BD003E4EC94CQ39044324-234DC59A-CFEE-477B-8CA8-30CEBB43F509Q39303557-DD3C1FA1-7067-4B8B-94DF-CC4BB49BFC9DQ40996093-7D5D004D-CAF2-4CDC-ADAD-DAE474D2BF7CQ48128911-0F524E6E-1C04-4E21-B847-CA2A731A830BQ50053733-91C7D1B5-5339-4A83-AF5E-77F4A9A5810AQ50120289-A9003E42-03E1-4AC4-BB86-B01CBBB189F6Q51168774-4B7F12C2-27A5-466D-B672-FE189327018FQ55100613-A67A7430-AB99-41FA-8A30-EB2DDE3DFF50Q55334068-E3E65821-F401-4DDD-8F96-77C573C8BFCF
P2860
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Molecular basis for antagonist ...... terferon-α receptor 1 antibody
@ast
Molecular basis for antagonist ...... terferon-α receptor 1 antibody
@en
type
label
Molecular basis for antagonist ...... terferon-α receptor 1 antibody
@ast
Molecular basis for antagonist ...... terferon-α receptor 1 antibody
@en
prefLabel
Molecular basis for antagonist ...... terferon-α receptor 1 antibody
@ast
Molecular basis for antagonist ...... terferon-α receptor 1 antibody
@en
P2093
P2860
P1476
Molecular basis for antagonist ...... terferon-α receptor 1 antibody
@en
P2093
Melissa M Damschroder
William F Dall'Acqua
P2860
P304
P356
10.1080/19420862.2015.1007810
P577
2015-01-01T00:00:00Z